Scientific American (blog)Has the Era of Gene Therapy Finally Arrived?Scientific American (blog)In 1990, geneticist William French Anderson injected cells with altered genes into a four-year-old girl with severe immunodeficiency disorder. This was the … Continue reading
CRISPR Without the CRISPR?GenomeWebA startup company called Homology Medicines says it can edit genes without using CRISPR, and has even raised $127 million to develop treatments based on this idea, Technology Review says. The company says it uses viru… Continue reading
FDA announces actions regarding stem cell treatmentsJD Supra (press release)Together with new guidance regarding the potential regulatory pathways for gene therapies, the FDA announced on Monday, August 28, 2017, that it will be taking action against c… Continue reading
FierceBiotechLexington biotech plots $86M IPO as key gene therapy trial nearsBoston Business JournalA Lexington biotech developing gene therapy treatments for rare eye diseases has announced plans to raise up to $86 million in an initial public offerin… Continue reading
MarketWatchWeekend roundup: Campbell in the soup | New cancer gene therapy | Exposing bad investment adviceMarketWatchNovartis AG NVS, -0.27% received FDA approval for the first cancer gene therapy available in the U.S. Emma Court explained how importa… Continue reading
|
Stem cell factor tied to reduced risk of cardiac events, death
Medical Xpress (HealthDay)—High levels of stem cell factor (SCF) are associated with reduced risk of mortality and cardiovascular events, according to a study published online Aug. 26 in the Journal of Internal Medicine. Harry Björkbacka, Ph.D., from Lund University … |
FiercePharma |
Gilead finds CAR–T manufacturing costly but says Kite’s is ‘superb’ and cost-efficient
FiercePharma Gilead Sciences is betting nearly $12 billion on Kite Pharma’s CAR–T technology, and one of the factors that influenced it is Kite’s readiness to handle the complex and time-sensitive manufacturing and logistics demanded by the personalized cell … Bio Roundup: CAR–T’s Huge Week, Merck’s ‘Pib Choice & MoreXconomy Gilead’s Acquisition Of Kite Pharma Relieves Shareholders’ EnnuiSeeking Alpha |